The evolution and current paradigm of chemotherapy for metastatic castrate-resistant prostate cancer

► Management of metastatic/advanced prostate cancer complex. ► Androgen deprivation therapy mainstay of initial management. ► Patients eventually develop castrate resistance. ► New agents demonstrate survival advantage and improved quality of life ► in this setting. ► Future challenges in optimum sequencing and combination of these agents.